Champions Oncology, Inc. (CSBR) stock
CSBRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends April 30
Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 11, 2026Score 9/30246% above fair value
$4.71+0.05 (+1.18%)
Close on Nov 13, 2026Market cap $65.49MP/E –Yield –
Champions Oncology total assets
Total assets on the balance sheet at the end of each period.
Champions Oncology's total assets was $33.29M at Jul 31, 2026. For fiscal 2026 it was $26.99M, down 16.6% from the year before. Over ten years it grew 16.7% a year on average. The highest annual figure on record is $35.38M in fiscal 2022.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Apr 30, 2026 | $26.99M | -16.6% |
| FY2025 | Apr 30, 2025 | $32.34M | +23.8% |
| FY2024 | Apr 30, 2024 | $26.13M | -23.8% |
| FY2023 | Apr 30, 2023 | $34.31M | -3.0% |
| FY2022 | Apr 30, 2022 | $35.38M | +28.2% |
| FY2021 | Apr 30, 2021 | $27.59M | +33.0% |
| FY2020 | Apr 30, 2020 | $20.75M | +84.2% |
| FY2019 | Apr 30, 2019 | $11.27M | +39.5% |
| FY2018 | Apr 30, 2018 | $8.08M | +0.8% |
| FY2017 | Apr 30, 2017 | $8.01M | +38.7% |
| FY2016 | Apr 30, 2016 | $5.78M | -52.0% |
| FY2015 | Apr 30, 2015 | $12.05M | +35.9% |
| FY2014 | Apr 30, 2014 | $8.87M | -23.9% |
| FY2013 | Apr 30, 2013 | $11.65M | +68.3% |
| FY2012 | Apr 30, 2012 | $6.92M | -45.3% |
| FY2011 | Apr 30, 2011 | $12.65M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jul 31, 2026 | $33.29M | +9.0% |
| Q4 FY2026CQ1 2026 | Apr 30, 2026 | $26.99M | -16.6% |
| Q3 FY2026CQ4 2025 | Jan 31, 2026 | $28.45M | -7.1% |
| Q2 FY2026CQ3 2025 | Oct 31, 2025 | $30.16M | +19.5% |
| Q1 FY2026CQ2 2025 | Jul 31, 2025 | $30.55M | +22.5% |
| Q4 FY2025CQ1 2025 | Apr 30, 2025 | $32.34M | +23.8% |
| Q3 FY2025CQ4 2024 | Jan 31, 2025 | $30.63M | +14.3% |
| Q2 FY2025CQ3 2024 | Oct 31, 2024 | $25.24M | -10.8% |
| Q1 FY2025CQ2 2024 | Jul 31, 2024 | $24.93M | -16.6% |
| Q4 FY2024CQ1 2024 | Apr 30, 2024 | $26.13M | -23.8% |
| Q3 FY2024CQ4 2023 | Jan 31, 2024 | $26.79M | -25.9% |
| Q2 FY2024CQ3 2023 | Oct 31, 2023 | $28.29M | -22.2% |
| Q1 FY2024CQ2 2023 | Jul 31, 2023 | $29.91M | -13.0% |
| Q4 FY2023CQ1 2023 | Apr 30, 2023 | $34.31M | -3.0% |
| Q3 FY2023CQ4 2022 | Jan 31, 2023 | $36.15M | +7.6% |
| Q2 FY2023CQ3 2022 | Oct 31, 2022 | $36.36M | +24.1% |
| Q1 FY2023CQ2 2022 | Jul 31, 2022 | $34.39M | +22.3% |
| Q4 FY2022CQ1 2022 | Apr 30, 2022 | $35.38M | +28.2% |
| Q3 FY2022CQ4 2021 | Jan 31, 2022 | $33.58M | +33.0% |
| Q2 FY2022CQ3 2021 | Oct 31, 2021 | $29.30M | +13.7% |
| Q1 FY2022CQ2 2021 | Jul 31, 2021 | $28.11M | +23.2% |
| Q4 FY2021CQ1 2021 | Apr 30, 2021 | $27.59M | +33.0% |
| Q3 FY2021CQ4 2020 | Jan 31, 2021 | $25.26M | +67.6% |
| Q2 FY2021CQ3 2020 | Oct 31, 2020 | $25.76M | +84.7% |
| Q1 FY2021CQ2 2020 | Jul 31, 2020 | $22.82M | +70.8% |
| Q4 FY2020CQ1 2020 | Apr 30, 2020 | $20.75M | +84.2% |
| Q3 FY2020CQ4 2019 | Jan 31, 2020 | $15.08M | +38.2% |
| Q2 FY2020CQ3 2019 | Oct 31, 2019 | $13.95M | +36.2% |
| Q1 FY2020CQ2 2019 | Jul 31, 2019 | $13.36M | +59.2% |
| Q4 FY2019CQ1 2019 | Apr 30, 2019 | $11.27M | +39.5% |
| Q3 FY2019CQ4 2018 | Jan 31, 2019 | $10.91M | +53.8% |
| Q2 FY2019CQ3 2018 | Oct 31, 2018 | $10.24M | +57.7% |
| Q1 FY2019CQ2 2018 | Jul 31, 2018 | $8.39M | +29.8% |
| Q4 FY2018CQ1 2018 | Apr 30, 2018 | $8.08M | +0.8% |
| Q3 FY2018CQ4 2017 | Jan 31, 2018 | $7.10M | -6.0% |
| Q2 FY2018CQ3 2017 | Oct 31, 2017 | $6.49M | -19.3% |
| Q1 FY2018CQ2 2017 | Jul 31, 2017 | $6.47M | – |
| Q4 FY2017CQ1 2017 | Apr 30, 2017 | $8.01M | – |
| Q3 FY2017CQ4 2016 | Jan 31, 2017 | $7.55M | – |
| Q2 FY2017CQ3 2016 | Oct 31, 2016 | $8.04M | – |
See a number that looks wrong?